Radiotherapy in Preclinical Models of Brain Metastases: A Review and Recommendations for Future Studies

Int J Biol Sci. 2024 Jan 1;20(2):765-783. doi: 10.7150/ijbs.91295. eCollection 2024.

Abstract

Brain metastases (BMs) frequently occur in primary tumors such as lung cancer, breast cancer, and melanoma, and are associated with notably short natural survival. In addition to surgical interventions, chemotherapy, targeted therapy, and immunotherapy, radiotherapy (RT) is a crucial treatment for BM and encompasses whole-brain radiotherapy (WBRT) and stereotactic radiosurgery (SRS). Validating the efficacy and safety of treatment regimens through preclinical models is imperative for successful translation to clinical application. This not only advances fundamental research but also forms the theoretical foundation for clinical study. This review, grounded in animal models of brain metastases (AM-BM), explores the theoretical underpinnings and practical applications of radiotherapy in combination with chemotherapy, targeted therapy, immunotherapy, and emerging technologies such as nanomaterials and oxygen-containing microbubbles. Initially, we provided a concise overview of the establishment of AM-BMs. Subsequently, we summarize key RT parameters (RT mode, dose, fraction, dose rate) and their corresponding effects in AM-BMs. Finally, we present a comprehensive analysis of the current research status and future directions for combination therapy based on RT. In summary, there is presently no standardized regimen for AM-BM treatment involving RT. Further research is essential to deepen our understanding of the relationships between various parameters and their respective effects.

Keywords: Animal models; Brain metastasis; Combined modality therapy; Dose fractionation, Radiation; Radiotherapy.

Publication types

  • Review

MeSH terms

  • Brain Neoplasms* / secondary
  • Cranial Irradiation
  • Humans
  • Lung Neoplasms* / pathology
  • Melanoma* / therapy
  • Radiosurgery*
  • Retrospective Studies